Design Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Design Therapeutics, Inc. (DSGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.04% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-03-09
- Design Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -0.04%, a 166.67% decline from fiscal 2024.
- Design Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 0.06%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | -0.04% 10-K · filed 2026-03-09 |
| 2024-12-31 | 0.06% 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |